logo

For the Inventor, By the Inventor

Mountain View, CA, United States of America

Ping Huang

This inventor holds 16 USPTO granted patents and 2 EPO patents, primarily in Kinase Inhibitors. Top assignees: Sugen Incorporated, Exelixis, Inc., Kaken Pharmaceutical Company, Ltd.. Active years: 2002-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ping Huang. Retrieved from https://idiyas.com/inventor/ping-huang-6h3jfkex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

% Patents Active = 18.8

 

Average Co-Inventor Count = 6.5

ph-index = 6

Forward Citations = 150(Granted Patents)


Company Filing History:

goldMedal8 out of 157 
 
Sugen Incorporated
 patents
silverMedal4 out of 177 
 
Exelixis, Inc.
 patents
bronzeMedal4 out of 136 
 
Kaken Pharmaceutical Company, Ltd.
 patents
4. 4 out of 4 
 
Molecular Research Institute
 patents
where one patent can have more than one assignee

Years Active: 2002-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Pyrimidinones
CK2 Modulators
PIM Modulators
Kinase Inhibitors
Amide Derivatives
Protein Kinase
Phosphate Mimics
Amino Acid Derivatives
Indazoles
Triazolotriazine
Heteroaryl Compounds
Growth Hormone Secretagogues
16 patents (USPTO):Explore Patents
1. 8324231 - Pyrimidinones as casein kinase II (CK2) modulators (2012-12-04),
2. 8242129 - 6-phenylpyrimidinones as PIM modulators (2012-08-14),
3. 8163771 - 11 β-HSD1 modulators (2012-04-24),
4. 8076338 - Kinase modulators and methods of use (2011-12-13),
5. 7279573 - Amide derivatives (2007-10-09),
6. 7186832 - Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors (2007-03-06),
7. 7186716 - 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors (2007-03-06),
8. 7157460 - Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors (2007-01-02),
9. 7122548 - Triazolotriazine compounds and uses thereof (2006-10-17),
10. 7064121 - N-acylated lipophilic amino acid derivatives (2006-06-20),
11. 7053086 - 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors (2006-05-30),
12. 7022677 - Amide derivatives as growth hormone secretagogues (2006-04-04),
13. 6864250 - N-acylated lipophilic amino acid derivatives (2005-03-08),
14. 6635640 - 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors (2003-10-21),
15. 6596772 - Phosphate mimics and methods of treatment using phosphatase inhibitors (2003-07-22),

Title: The Innovative Contributions of Ping Huang

Introduction

Ping Huang is a notable inventor based in Mountain View, CA, with a remarkable portfolio of 16 patents. His work primarily focuses on the development of pharmaceutical compounds that target specific biological pathways, showcasing his expertise in medicinal chemistry.

Latest Patents

Among his latest patents, Huang has developed pyrimidinones as casein kinase II (CK2) modulators. These compounds, defined by a specific formula, serve as inhibitors of the CK2 pathways, which are crucial in various cellular processes. Additionally, he has worked on 6-phenylpyrimidinones as PIM modulators, which also involve unique chemical formulations and have potential therapeutic applications.

Career Highlights

Throughout his career, Ping Huang has made significant contributions to the pharmaceutical industry. He has worked with prominent companies such as Sugen Incorporated and Exelixis, Inc., where he has applied his innovative ideas to advance drug development.

Collaborations

Huang has collaborated with talented individuals in his field, including Chung Chen Wei and Peng Cho Tang. These partnerships have likely enhanced his research and contributed to the success of his projects.

Conclusion

Ping Huang's innovative work in the field of pharmaceuticals has led to the development of important compounds that may have significant therapeutic implications. His contributions continue to impact the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…